InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 232570

Tuesday, 09/20/2016 8:13:41 PM

Tuesday, September 20, 2016 8:13:41 PM

Post# of 345950

Piper Jaffray's Charles Duncan recently initiated coverage at Peregrine. You may want to watch this video which showcases Charles Duncan talking..



Well, it certainly looks like some are going to look quite foolish by dropping coverage of Peregrine Pharmaceuticals, one of the very biggest emerging biotechs. I did say emerging.... and if one has followed the puzzle pieces you would have already known it has emerged already.

-----------------------------------------------------------

Analyst Information

Charles Duncan, PhD
Sr. Research Analyst
Charles Duncan, PhD

Charles Duncan, Ph.D., joined Piper Jaffray in 2012 as a managing director and senior research analyst focused on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 20 years of sell-side experience during which he has covered a broad range of biopharma companies, most recently serving as an analyst at JMP Securities since 2002. Previously, Duncan covered the sector at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the Financial Times and StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. Duncan began his career as a manager of clinical development at Global Drug Development, Inc., a pharmaceutical development consulting firm, and he also launched InfusionVision Medical, a venture-backed start-up medical device company. He is a graduate of the University of Wisconsin-Madison and holds a doctorate in pharmaceutical sciences with a concentration in neuropharmacology from the University of Colorado.

Associates:
Sarah Weber
Research Analyst
Universe Coverage:

Healthcare: Emerging BioPharma

ACAD ACADIA Pharmaceuticals Inc.
AIMT Aimmune Therapeutics, Inc.
ADHD Alcobra Ltd
ARGS Argos Therapeutics, Inc.
AXON Axovant Sciences Ltd.
BCRX BioCryst Pharmaceuticals, Inc.
CARA Cara Therapeutics Inc.
CPRX Catalyst Pharmaceuticals, Inc.
CLCD CoLucid Pharmaceuticals, Inc.
CORT Corcept Therapeutics Inc.
CTIC CTI BioPharma Corp.
CYTK Cytokinetics, Incorporated
GERN Geron Corporation
HALO Halozyme Therapeutics, Inc.
INO Inovio Pharmaceuticals, Inc.
ITCI Intra-Cellular Therapies, Inc.
NANO FP Nanobiotix SA
NBIX Neurocrine Biosciences Inc.
NWRN SW Newron Pharmaceuticals
RETA Reata Pharmaceuticals, Inc.
SGMO Sangamo BioSciences, Inc.
SPHS Sophiris Bio, Inc.
VBLT Vascular Biogenics Ltd.
VTVT vTv Therapeutics, Inc.
ZYNE Zynerba Pharmaceuticals, Inc.

http://www.piperjaffray.com/2col.aspx?id=7&analystid=1275&title=Analyst%20Information%20for%20Charles%20Duncan,%20PhD


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News